269 related articles for article (PubMed ID: 23782076)
1. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
3. Primary therapy of Waldenström macroglobulinemia with nucleoside analogue-based therapy.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):227-30. PubMed ID: 23531544
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine-based combination therapies for Waldenström's macroglobulinemia.
Tedeschi A; Alamos SM; Ricci F; Greco A; Morra E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):67-70. PubMed ID: 19362977
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
6. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
7. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
8. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
9. Fludarabine treatment in resistant Waldenstrom's macroglobulinemia.
Zinzani PL; Gherlinzoni F; Bendandi M; Zaccaria A; Aitini E; Salvucci M; Tura S
Eur J Haematol; 1995 Feb; 54(2):120-3. PubMed ID: 7698295
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
11. Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Johnson SA
Hematol J; 2004; 5 Suppl 1():S50-61. PubMed ID: 15079153
[TBL] [Abstract][Full Text] [Related]
12. Waldenström's macroglobulinemia.
McKenna JA
Clin J Oncol Nurs; 2002; 6(5):283-6. PubMed ID: 12240489
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Crowley JJ; Barlogie B
Semin Oncol; 2003 Apr; 30(2):220-5. PubMed ID: 12720140
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Shin SJ; Chun SH; Kim KO; Kim MK; Lee KH; Hyun MS; Cho HS
Jpn J Clin Oncol; 2005 Oct; 35(10):622-5. PubMed ID: 16172172
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine therapy in Waldenström's macroglobulinemia.
Dimopoulos MA; O'Brien S; Kantarjian H; Pierce S; Delasalle K; Barlogie B; Alexanian R; Keating MJ
Am J Med; 1993 Jul; 95(1):49-52. PubMed ID: 8328496
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenström's macroglobulinemia.
Tedeschi A; Ricci F; Goldaniga MC; Benevolo G; Varettoni M; Motta M; Pioltelli P; Gini G; Barate' C; Luraschi A; Vismara E; Frustaci AM; Nichelatti M; Vitolo U; Baldini L; Morra E
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):231-4. PubMed ID: 23490992
[TBL] [Abstract][Full Text] [Related]
17. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
18. Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K; Tan J; Wu T
Cochrane Database Syst Rev; 2009 Jan; (1):CD006719. PubMed ID: 19160296
[TBL] [Abstract][Full Text] [Related]
19. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Johnson SA; Owen RG; Oscier DG; Leblond V; Levy V; Jaeger U; Seymour JF
Clin Lymphoma; 2005 Mar; 5(4):294-7. PubMed ID: 15794869
[TBL] [Abstract][Full Text] [Related]
20. Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
Hałaburda K; Hellmann A
Acta Haematol Pol; 1994; 25(1):63-7. PubMed ID: 8209618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]